Trial Profile
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms J-EMPHASIS-HF
- Sponsors Pfizer
- 19 Aug 2017 Results published in the Circulation Journal
- 29 Dec 2016 Results of post-hoc population pharmacokinetic analysis published in the Journal of Clinical Pharmacology
- 05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.